Preclinical evaluation of89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys
Open Access
- 9 December 2013
- journal article
- Published by Taylor & Francis in mAbs
- Vol. 6 (2) , 567-575
Abstract
RG7356 is a humanized antibody targeting the constant region of CD44. RG7356 was radiolabeled with 89Zr for preclinical evaluations in tumor xenograft-bearing mice and normal cynomolgus monkeys to enable study of its biodistribution and the role of CD44 expression on RG7356 uptake. Studies with 89Zr-RG7356 were performed in mice bearing tumor xenografts that differ in the level of CD44 expression (CD44+ or CD44-) and RG7356 responsiveness (resp or non-resp): MDA-MB-231 (CD44+, resp), PL45 (CD44+, non-resp) and HepG2 (CD44–, non-resp). Immuno-PET whole body biodistribution studies were performed in normal cynomolgus monkeys to determine normal organ uptake after administration of a single dose. At 1, 2, 3, and 6 days after injection, 89Zr-RG7356 uptake in MDA-MB-231 (CD44+, resp) xenografts was nearly constant and about 9 times higher than in HepG2 (CD44–, non-resp) xenografts (range 27.44 ± 12.93 to 33.13 ± 7.42% ID/g vs. 3.25 ± 0.38 to 3.90 ± 0.58% ID/g). Uptake of 89Zr-RG7356 was similar in MDA-MB-231 (CD44+, resp) and PL45 (CD44+, non-resp) xenografts. Studies in monkeys revealed antibody uptake in spleen, salivary glands and bone marrow, which might be related to the level of CD44 expression. 89Zr-RG7356 uptake in these normal organs decreased with increasing dose levels of unlabeled RG7356. 89Zr-RG7356 selectively targets CD44+ responsive and non-responsive tumors in mice and CD44+ tissues in monkeys. These studies indicate the importance of accurate antibody dosing in humans to obtain optimal tumor targeting. Moreover, efficient binding of RG7356 to CD44+ tumors may not be sufficient in itself to drive an anti-tumor response.Keywords
This publication has 29 references indexed in Scilit:
- Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44Proceedings of the National Academy of Sciences, 2013
- Global Quantitative Phosphoproteome Analysis of Human Tumor Xenografts Treated with a CD44 AntagonistCancer Research, 2012
- PET and MRI of Metastatic Peritoneal and Pulmonary Colorectal Cancer in Mice with Human Epidermal Growth Factor Receptor 1–Targeted 89Zr-Labeled PanitumumabJournal of Nuclear Medicine, 2012
- Physiological Contribution of CD44 as a Ligand for E-Selectin during Inflammatory T-Cell RecruitmentThe American Journal of Pathology, 2011
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010
- Phase I Biodistribution and Pharmacokinetic Study of Lewis Y–Targeting Immunoconjugate CMD-193 in Patients with Advanced Epithelial CancersClinical Cancer Research, 2009
- Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and ChallengesBioconjugate Chemistry, 2009
- Involvement of CD44, a molecule with a thousand faces, in cancer disseminationSeminars in Cancer Biology, 2008
- Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer PatientsClinical Cancer Research, 2006
- Expression and modulation of CD44 variant isoforms in humansJournal of Cell Biology, 1994